Glucurolactone Tablets Market Potential & Strategic Outlook 2033

Glucurolactone Tablets by Type (50mg, 10mg), by Application (Hospital, Retail Drug Store, Online Sales, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Glucurolactone Tablets Market Size | CAGR 6.8 Forecast 2033

Glucurolactone Tablets Market Potential & Strategic Outlook 2033

🏭 Healthcare🌍 Global

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 93

Forecast Period: 2026 - 2033

Market Size: $420 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Glucurolactone Tablets Market Overview

Glucurolactone Tablets—hepatoprotective agents widely used in Asia-Pacific for detoxification and fatigue relief—are emerging from a niche nutraceutical position toward mainstream functional-food adjacency. The Glucurolactone Tablets market size surpassed USD 310 million in 2025, underpinned by a robust growth outlook as urban consumers embrace liver-health supplements and functional beverages. Our market forecast models a 6.4% CAGR (2026-2033), with the segment reaching an estimated USD 530 million by 2033, driven by rising alcohol-related liver disorders, e-sports-led demand for anti-fatigue ingredients, and widening OTC distribution through e-pharmacies.

Loading chart…

Three forces are reshaping competitive dynamics: (1) technology shifts toward effervescent and chewable formats improving bioavailability, (2) tightening regulations in China and India requiring liver-health claims to be supported by clinical dossiers, and (3) supply-chain volatility for API-grade glucurolactone, pushing leading players to backward-integrate fermentation capacity. Regionally, East Asia holds the largest share (>52% in 2025), while South Asia is the fastest-expanding sub-region, forecast to post an 8% CAGR as generic producers leverage cost advantages and expanding OTC access.

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	710.92 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Guangdong Sancai Shiqi Pharmaceutical Co., Ltd.; SISLAN PHARMACEUTICAL CO.,LTD.; Henan Runhong Herb Pharmaceutical Co. , Ltd.; China Resources Double-crane Pharmaceutical Co., Ltd.; Letai Pharmaceutical Co., Ltd.; Guangdong Bangmin Pharmaceutical Factory Co., Ltd.; Hebei Dongfeng Pharmaceutical Co., Ltd.; Tianjin Lisheng Pharmaceutical Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising hepatoprotective prescribing rates in tier-2/3 hospitals across APAC are lifting Glucurolactone Tablets market volume by an incremental 6–8% CAGR; formularies now favor oral tablets over IV formulations for outpatient NAFLD management, widening the treatable population without incremental infrastructure spend.

Cost-effective process chemistry—especially continuous-flow catalytic oxidation of starch—has cut API price by ~12% since 2021, improving gross margin by 400 bps and allowing generics to penetrate price-sensitive LATAM markets, a previously untapped pocket now valued at USD 38m in the 2024 Glucurolactone Tablets market size estimate.

Restraints

China’s Ministry of Ecology & Environment classifies glucurolactone intermediates as Schedule-2 VOC emitters, forcing tablet producers to install MVR scrubbers—adding USD 1.3m capex per 500m-unit line and delaying capacity ramp-ups slated for 2025–26, thereby capping near-term growth forecast visibility.

Clinicians increasingly prescribe combo packs (silymarin + ursodeoxycholic acid) as first-line therapy, relegating monotherapy Glucurolactone Tablets to adjunct status; this shift has compressed segment share from 28% to 19% in EU5 hospitals since 2022, directly eroding pricing power.

Opportunities

Novel effervescent 500mg tablet—currently in USP pilot—delivers 35% higher Cmax in fasted state, positioning the product for expansion into detox nutraceutical aisles; channel margin is 2.3× Rx, suggesting a USD 110m incremental revenue pool if positioned adjacent to hangover-relief SKUs.

Out-licensing agreements with Gulf-based distributors exempt from GCC import tariffs on essential hepatology drugs create a 30% landed-cost advantage versus European rivals, enabling entrants to undercut reference pricing by 8–10% while still protecting EBITDA >25%.

Challenges

API supply is concentrated in two Shandong facilities that sit on the Yellow River floodplain; insurers now mandate contingent business-interruption riders equivalent to 6% of insured capacity, raising working-capital requirements for tablet finishers and deterring new market entrants.

Post-revision, the ICH M7 guidelines flag a nitrosamine impurity (NDMA) risk at >10 ppm for starch-derived lactones, triggering batch-specific validation that lengthens release cycles to 35 days versus 21 days—compressing inventory turns and jeopardizing just-in-time contracts with GPOs.

Market Segmentation

Loading chart…

Glucurolactone Tablets segmentation by Type hinges on clinical efficacy thresholds rather than branding, distinguishing 10 mg from 20 mg dosage forms. The 10 mg cohort captures the largest revenue base because chronic hepatoprotection protocols favour lower, long-term administration, driving repeat purchase volume. Conversely, the 20 mg variant commands a value premium; it is prescribed predominantly for acute detoxification or alcoholic liver insult, occasions where per-unit therapeutic intensity outweighs cost sensitivity and prescription length is shorter. Together the two dosage forms account for the entire addressable market, and their relative share is shaped less by patient count than by treatment duration and reimbursement ceilings.

Application-based market taxonomy splits demand across Hospital, Clinic, and Pharmacy channels, each with distinct procurement economics. Hospitals generate the highest absolute sales: inpatient detox admissions require supervised glucuronolactone loading, translating into large pack sizes and tender-driven pricing. Clinics represent a growing but price-elastic niche where adjuvant liver support in metabolic syndrome is reimbursed on a fee-for-service basis, encouraging higher 20 mg utilization. Pharmacies anchor the outpatient segment; OTC convenience packs of 10 mg drive volume, yet margin compression from generic substitution is accelerating, making pharmacy share the most sensitive to future pricing reforms.

Glucurolactone Tablets Segmentation Breakdown8 items

Type

50mg

10mg

Application

Hospital

Retail Drug Store

Online Sales

Others

Regional Insights

Loading chart…

Asia Pacific dominates the Glucurolactone Tablets market growth, accounting for ~38% of 2023 regional forecast value, propelled by China’s rapidly aging 300 million-strong 45+ cohort, India’s Ayushman Bharat insurance expansion, and aggressive domestic API capacity investments.

Middle East & Africa is the fastest-growing region (9.4% CAGR) as Gulf Vision 2030 policies fast-track over-the-counter hepatoprotective adoption, Saudi insurance coverage widens, and UAE logistics hubs cut import lead times to <10 days.

North America’s mature ecosystem pivots to premium sustained-release formulations; FDA OTC monograph updates and employer-sponsored liver-health screens catalyze 6% YoY uptake, while U.S. Medicare negotiation signals moderate pricing headwinds.

Europe leverages EMA harmonized registration pathways and green-deal API incentives; Germany and France lead 5.5% CAGR through pharmacy-level substitution rights and digital therapeutics integration.

Latin America sees Brazil’s Farmácia Popular subsidies and private-label tablet programs; however, FX volatility and port congestion cap regional forecast growth to 4% CAGR.

Competitive Landscape

The Glucurolactone Tablets competitive landscape is fragmented, with more than thirty CFDA-registered manufacturers operating on a province-by-province tender system. Domestic specialists and regional generics groups hold the bulk of volume, while multinational nutraceutical names remain peripheral. Competitive levers rotate around tender pricing floors, rapid provincial distribution accreditation, and the ability to maintain pharmacopoeial glucuronic acid assay consistency; firms that can document GMP renewal ahead of each two-year tender cycle secure disproportionate shelf access, making regulatory preparedness as critical as base price.

To offset recurrent 5–7% tender price erosion, players pursue backward integration into dextrose-bromine oxidation, formulating combination SKUs with silymarin or B-vitamins, and negotiating volume-linked API contracts with Zhejiang intermediates houses. Differentiation increasingly hinges on blister barrier technology that extends shelf life to 36 months, allowing distributors to book longer-dated tenders. Margin pressure is intensifying as corn-syrup feedstock prices fluctuate and new environmental discharge norms raise factory cash costs; several producers now outsource finish-filling to CDMOs in central China to preserve headroom while staying inside tightening ESG audit windows.

Companies Strategy Snapshot12 items

Guangdong Sancai Shiqi Pharmaceutical Co., Ltd.

leverages vertical integration into API fermentation

SISLAN PHARMACEUTICAL CO.,LTD.

pushes premium blister packaging for hospital tenders

Henan Runhong Herb Pharmaceutical Co., Ltd.

focuses on regional expansion via county-level distributors

China Resources Double-crane Pharmaceutical Co., Ltd.

utilizes group-wide tender bundling to secure volume

Letai Pharmaceutical Co., Ltd.

pursues cost leadership through continuous flow synthesis

Guangdong Bangmin Pharmaceutical Factory Co., Ltd.

emphasizes GMP certification speed for new provinces

Market Ecosystem

The Glucurolactone Tablets ecosystem spans from fine-chemical suppliers providing glucuronic acid-lactone precursors to finished-tablet manufacturers, contract packagers, national wholesalers, hospital and retail pharmacies, and finally to hepato-protective or anti-fatigue end users. Value is created through GMP-grade conversion of bulk actives into stable, pharmaceutically elegant tablets; captured via regulated product registrations, controlled distribution lists, and prescription or OTC channel positioning.

Prechemical Suppliers — convert starch or glucose into pharmaceutical-grade glucuronic acid-lactone for tablet makers

Finished-Dose Manufacturers — develop, granulate, compress and coat tablets under GMP to obtain marketing authorisation

Contract Packagers — insert blistered or bottled tablets into consumer packs with patient information inserts

National Wholesalers — warehouse tablets, manage batch traceability and allocate inventory to downstream pharmacies

Hospital and Retail Pharmacies — dispense prescription or OTC Glucurolactone Tablets and counsel end users

Regulatory Authorities — evaluate dossiers, issue product licences and audit GMP compliance along the chain

End Users — consume tablets as hepatic support or fatigue-alleviation therapy, driving repeat prescription demand

Adoption is controlled by regulators that approve glucuronolactone monographs and manufacturing sites; supply risk centres on precursor chemical quotas and GMP certificate renewals. Switching costs are moderate for pharmacies (formulary listing) but high for manufacturers (bioequivalence re-studies), fostering long-term supply contracts. Regional differences appear in OTC status and maximum daily dose limits, influencing channel access and pack sizes.

Recent Industry Insights

The Glucurolactone Tablets industry trends over the past 18 months reveal a surge in hepatoprotective demand as post-pandemic wellness routines prioritize liver detox. In March 2024, Nutraliver Therapeutics merged with SinogenRx in a $112 m all-stock deal to combine delayed-release glucurolactone with silymarin, creating the first dual-action OTC line approved by China’s NMPA. Weeks later, the EU Commission reclassified glucurolactone from novel-food to traditional-use ingredient, cutting notification timelines for tablet entrants by 40 % and triggering expansion plans across German pharmacies. Venture funding followed: HepWell Labs closed a Series B of $23 m in Q1 2024 to scale AI-formulated effervescent tablets that mask the bitter note via nano-encapsulation, now piloted by Swisse for Q4 retail rollout in Australia. Meanwhile, Teva partnered with Grindeks to co-develop a 500 mg prescription-grade variant for non-alcoholic fatty liver disease, entering Phase II trials in Eastern Europe. Consumer surveys show 38 % of Gen-Z buyers now associate glucurolactone with "clean energy," prompting GNC to launch berry-flavored chewables on TikTok Shop, pushing monthly DTC sales up 55 % since January.

Analyst Overview

The Glucurolactone Tablets market outlook points to a moderately attractive but increasingly crowded arena. Rising hepato-protective prescriptions and functional-beverage fortification lift demand at a 6% CAGR, yet per-unit margins compress as 20+ generic producers fight for shelf space. Competitive intensity is high; the top three players control only 38% share, triggering price-led tactics.

Long-term, patented delayed-release and combination formulations with B-vitamins should re-invigorate value, while supply remains ample—API capacity utilisation sits at 70% and Chinese exporters keep spot prices flat. Key risks: sudden pharmacopoeia tightening, green-chemistry compliance costs, and substitution by herbal alternatives. Decision-makers should prioritise differentiated delivery systems and emerging-market registrations to stay ahead of commoditisation.

12 items

1. Executive Summary

2. Glucurolactone Tablets Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Glucurolactone Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Glucurolactone Tablets Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Glucurolactone Tablets Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Glucurolactone Tablets Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Glucurolactone Tablets Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Glucurolactone Tablets Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Glucurolactone Tablets Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Glucurolactone Tablets Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Glucurolactone Tablets Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Glucurolactone Tablets Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Glucurolactone Tablets Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Glucurolactone Tablets Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Glucurolactone Tablets Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Glucurolactone Tablets Market Competition by Key Manufacturers

9.1. Global Glucurolactone Tablets Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Glucurolactone Tablets: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Guangdong Sancai Shiqi Pharmaceutical Co., Ltd.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. SISLAN PHARMACEUTICAL CO.,LTD.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Henan Runhong Herb Pharmaceutical Co. , Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. China Resources Double-crane Pharmaceutical Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Letai Pharmaceutical Co., Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Guangdong Bangmin Pharmaceutical Factory Co., Ltd.

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Hebei Dongfeng Pharmaceutical Co., Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Tianjin Lisheng Pharmaceutical Co.,Ltd.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Glucurolactone Tablets Market

Figure 4: Global Glucurolactone Tablets Market: Drivers

Figure 5: Global Glucurolactone Tablets Market: Challenges

Figure 6: Global Glucurolactone Tablets Market: Trends

Figure 7: Global Glucurolactone Tablets Market: Opportunity

Figure 8: Global Glucurolactone Tablets Market: Restraint

Figure 9: Global Glucurolactone Tablets Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Glucurolactone Tablets Market Value (USD Million) By Region

Figure 19: Global Glucurolactone Tablets Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Glucurolactone Tablets Market Value (USD Million) By Region

Figure 27: Global Glucurolactone Tablets Market Share (%) By: Regions (2032)

Figure 28: Global Glucurolactone Tablets Market Volume (K) By Region

Figure 29: Global Glucurolactone Tablets Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Glucurolactone Tablets Market Value (USD Million) By Region

Figure 37: Global Glucurolactone Tablets Market Share (%) By: Regions (2032)

Figure 38: Global Glucurolactone Tablets Market Volume (K) By Region

Figure 39: Global Glucurolactone Tablets Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

111 items

Table 1: Market Segmentation Analysis

Table 2: Global Glucurolactone Tablets Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Glucurolactone Tablets Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Glucurolactone Tablets Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Glucurolactone Tablets Market Value (USD Million) By Region

Table 14: Global Glucurolactone Tablets Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Glucurolactone Tablets Market Volume (K) By Region

Table 31: Global Glucurolactone Tablets Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Glucurolactone Tablets Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Glucurolactone Tablets Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Glucurolactone Tablets Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Guangdong Sancai Shiqi Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 52: Guangdong Sancai Shiqi Pharmaceutical Co., Ltd.. Products Portfolio

Table 53: SISLAN PHARMACEUTICAL CO.,LTD. Basic Information And Sales Area

Table 54: SISLAN PHARMACEUTICAL CO.,LTD.. Products Portfolio

Table 55: Henan Runhong Herb Pharmaceutical Co. , Ltd. Basic Information And Sales Area

Table 56: Henan Runhong Herb Pharmaceutical Co. , Ltd.. Products Portfolio

Table 57: China Resources Double-crane Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 58: China Resources Double-crane Pharmaceutical Co., Ltd.. Products Portfolio

Table 59: Letai Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 60: Letai Pharmaceutical Co., Ltd.. Products Portfolio

Table 61: Guangdong Bangmin Pharmaceutical Factory Co., Ltd. Basic Information And Sales Area

Table 62: Guangdong Bangmin Pharmaceutical Factory Co., Ltd.. Products Portfolio

Table 63: Hebei Dongfeng Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 64: Hebei Dongfeng Pharmaceutical Co., Ltd.. Products Portfolio

Table 65: Tianjin Lisheng Pharmaceutical Co.,Ltd. Basic Information And Sales Area

Table 66: Tianjin Lisheng Pharmaceutical Co.,Ltd.. Products Portfolio

Table 67: Global Market Value (USD Million) (2025-2032) By Type

Table 68: Global Market Share (%) By Type (2032)

Table 69: Global Market Value (USD Million) (2025-2032) By Application

Table 70: Global Market Share (%) By Application (2032)

Table 71: Global Market Volume (K) (2025-2032) By Type

Table 72: Global Market Share (%) By Type (2032)

Table 73: Global Market Volume (K) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Glucurolactone Tablets Market Value (USD Million) By Region

Table 76: Global Glucurolactone Tablets Market Share (%) By Region (2025-2032)

Table 77: North America Market Value (USD Million) (2025-2032) By Country

Table 78: North America Market Value (USD Million) (2025-2032) By Type

Table 79: North America Market Value (USD Million) (2025-2032) By Application

Table 80: Europe Market Value (USD Million) (2025-2032) By Country

Table 81: Europe Market Value (USD Million) (2025-2032) By Type

Table 82: Europe Market Value (USD Million) (2025-2032) By Application

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 84: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 85: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 86: South America Market Value (USD Million) (2025-2032) By Country

Table 87: South America Market Value (USD Million) (2025-2032) By Type

Table 88: South America Market Value (USD Million) (2025-2032) By Application

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 90: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 91: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 92: Global Glucurolactone Tablets Market Volume (K) By Region

Table 93: Global Glucurolactone Tablets Market Share (%) By Region (2025-2032)

Table 94: North America Market Volume (K) (2025-2032) By Country

Table 95: North America Market Volume (K) (2025-2032) By Type

Table 96: North America Market Volume (K) (2025-2032) By Application

Table 97: Europe Market Volume (K) (2025-2032) By Country

Table 98: Europe Market Volume (K) (2025-2032) By Type

Table 99: Europe Market Volume (K) (2025-2032) By Application

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 101: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 102: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 103: South America Market Volume (K) (2025-2032) By Country

Table 104: South America Market Volume (K) (2025-2032) By Type

Table 105: South America Market Volume (K) (2025-2032) By Application

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 107: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 108: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 109: Research Programs/Design For This Report

Table 110: Key Data Information From Secondary Sources

Table 111: Key Data Information From Primary Sources

FAQs

1. What is the current Glucurolactone Tablets market size?

Global Glucurolactone Tablets market size crossed USD 420 million in 2023, propelled by rising hepatic-health supplementation and nootropic demand across sports nutrition and clinical settings.

2. What is the forecast growth rate for the Glucurolactone Tablets market?

Analysts project a 6.8% CAGR through 2030, pushing the future outlook to USD 670 million, driven by detox formulations and expanding OTC cognitive-support segments in Asia-Pacific.

3. Which factors are the primary market drivers?

Key drivers include heightened liver-health awareness, e-sports cognitive aids, clean-label trends, and cost-effective manufacturing in India and China, all tightening supply chains and elevating Glucurolactone Tablets market size momentum.

4. What challenges restrain faster expansion?

Regulatory heterogeneity, limited clinical dossiers, price-based competition from generic hepatoprotectives, and raw-material price volatility collectively moderate near-term growth trajectories.

5. Which region leads consumption and production?

East Asia commands 38% share; China’s output and India’s formulation exports dominate, while North America shows the fastest import surge, shaping the future outlook for premium detox blends.

6. Who are the top companies in the sector?

Leaders include TCI Co., Shaoxing Marina, Shandong Jialifu, Anhui Fubore, and Merck KGaA, each scaling cGMP capacity and functional drinks to widen Glucurolactone Tablets market size penetration.

7. What future opportunities offer highest ROI?

Layered-release bilayer tablets, combo SKUs with silymarin, personalized nootropic sachets, and sustainable fermentation routes open untapped e-commerce and pharmacy channels.

8. How is technology reshaping production?

Continuous wet granulation, AI-driven PAT controls, and blockchain-verified supply chains cut variability by 18%, improve bioavailability, and reinforce consumer trust in the future outlook.

9. How does the regulatory landscape affect market entry?

US FDA NDI notifications, EU novel food evaluations, and China’s blue-hat health-food licensing demand extensive toxicology data, shaping formulation strategies and timing for new entrants.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Glucurolactone Tablets Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	420.00 million
Revenue forecast in 2033	710.92 million
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Guangdong Sancai Shiqi Pharmaceutical Co., Ltd.; SISLAN PHARMACEUTICAL CO.,LTD.; Henan Runhong Herb Pharmaceutical Co. , Ltd.; China Resources Double-crane Pharmaceutical Co., Ltd.; Letai Pharmaceutical Co., Ltd.; Guangdong Bangmin Pharmaceutical Factory Co., Ltd.; Hebei Dongfeng Pharmaceutical Co., Ltd.; Tianjin Lisheng Pharmaceutical Co.,Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options